Quantcast

Latest Eisai Co. Ltd. Stories

2014-09-17 04:20:02

Tokyo, Sept 17, 2014 - (JCN Newswire) - Eisai Co., Ltd. announced today that a series of abstracts highlighting the latest clinical data on Halaven(R) (generic name: eribulin mesylate; non-taxane microtubule dynamics inhibitor, "Halaven") and lenvatinib mesylate (generic name; selective inhibitor of receptor tyrosine kinases (RTKs) with a novel binding mode, "lenvatinib") will be presented during the 39th European Society for Medical Oncology (ESMO) Congress...

2014-09-15 20:22:06

Seven New Grant Investments for $15.3 Million to Tackle Malaria, Chagas Disease and Dengue, which is Dramatically on the Rise TOKYO, Sept. 15, 2014 /PRNewswire-USNewswire/ -- The Global Health Innovative Technology Fund (GHIT Fund), a new public health partnership that is bringing Japanese know-how and investment to the global fight against infectious diseases, today announced seven grant investments totaling US$15.3 million to speed the development of promising drugs and vaccines to battle...

2014-08-29 20:22:07

DUBLIN, Ireland, August 29, 2014 /PRNewswire/ -- Research and Markets ( http://www.researchandmarkets.com/research/jjj5vs/global_peptic) has announced the addition of the "Global Peptic Ulcer Drugs Market 2014-2018" [http://www.researchandmarkets.com/research/jjj5vs/global_peptic ] report to their offering. A peptic ulcer is an open lesion that develops on the mucosal lining of the stomach and small intestine because of the caustic effect of the gastric acids and...

2014-08-20 04:20:01

Eisai Submits Applications for Antiepilepsy Agent Fycompa Simultaneously In Europe and U.S. Seeking Indication Expansion as Adjunctive Treatment of Primary Generalized Tonic-Clonic Seizures Tokyo, Aug 20, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has submitted applications to regulatory authorities in the U.S. and Europe (the FDA and EMA respectively) for the...

2014-07-03 20:20:02

Tokyo, July 3, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") announced today that it has received approval from the European Commission of the indication expansion of Halaven (generic name: eribulin mesylate, "eribulin") to contribute to earlier treatment of patients with locally advanced or metastatic breast cancer who have progressed after at least one chemotherapeutic regimen for advanced disease. Prior therapy should...

2014-07-01 16:27:12

LONDON, July 1, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report: Global Alzheimer%s Drugs Market 2014-2018http://www.reportbuyer.com/pharma_healthcare/therapeutic/global_alzheimer_s_drugs_market_2012_2016.html About Alzheimer's DiseaseAlzheimer's disease is a progressive, irreversible degeneration of the brain that disrupts the thinking, language, behavioral and cognitive skills of a person. AD is more prevalent in people aged 65 years or above and...

2014-06-23 08:29:15

WOODCLIFF LAKE, N.J., June 23, 2014 /PRNewswire/ -- Eisai Inc., the U.S. pharmaceutical subsidiary of Eisai Co., Ltd., today announces the immediate appointment of Barry Lederman to the position of Vice President and Chief Financial Officer (CFO). In this role, Mr. Lederman will have full oversight and responsibility for leading Eisai's financial operations in the Americas Region. He also will serve as a member of the company's Executive Committee....

2014-05-27 04:20:05

Indication of Anticancer Agent Halaven for Use in Earlier-Line Treatment of Advanced Breast Cancer Tokyo, May 27, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that its U.K. subsidiary Eisai Europe Limited has received a positive opinion from the European Medicines Agency's (EMA) Committee for Medicinal Products for Human Use (CHMP) on the indication expansion...

2014-05-27 04:20:02

Contains 5 Ingredients that Help Bring Out the Beauty From Within & Sodium Supplement Tokyo, May 27, 2014 - (JCN Newswire) - Eisai Co., Ltd. (Headquarters: Tokyo, President & CEO: Haruo Naito, "Eisai") announced today that it will launch its new carbonated supplement drink Chocola BB Sparkling Salty Natsumikan* Flavor, classified as a Food with Nutrient Function Claims, in Japan on Monday, June 2.Chocola BB Sparkling Salty...

2014-04-29 20:23:44

LONDON, April 29, 2014 /PRNewswire/ -- Reportbuyer.com has added a new market research report:The World Market for Orphan Drugshttp://www.reportbuyer.com/pharma_healthcare/therapeutic/world_market_orphan_drugs_1.htmlIn recent years, there has been a substantial increase in the number of drugs available to treat rare ("orphan") diseases. This comprehensive report, The World Market for Orphan Drugs, looks at this trend and provides estimates for the market opportunity in the U.S.,...


Word of the Day
vermicular
  • Like a worm in form or movement; vermiform; tortuous or sinuous; also, writhing or wriggling.
  • Like the track or trace of a worm; appearing as if worm-eaten; vermiculate.
  • Marked with fine, close-set, wavy or tortuous lines of color; vermiculated.
  • A form of rusticated masonry which is so wrought as to appear thickly indented with worm-tracks.
This word ultimately comes from the Latin 'vermis,' worm.
Related